

Ref: MHL/Sec&Legal/2025-26/58

September 18, 2025

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

In continuation to our intimation dated August 07, 2025, we wish to inform that the Company has acquired ‘Dr. RS Patil’s Ambika Pathology Laboratory’ (‘Ambika Pathology’), a sole proprietorship firm of Dr. Rajendra Sadashiv Patil, as a going concern, effective September 18, 2025 as per the agreed terms under the Business Transfer Agreement (‘BTA’). The other terms and conditions, including deferred consideration, will be carried out in accordance with the BTA.

Consequent to above transfer, the operations of Ambika Pathology are now being carried out under the Company, effective September 18, 2025.

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh C Kulkarni
Head – Legal & Secretarial

